Bio-Connect
Chemical Structure
Chemical Structure
Chemical Structure

Oxaliplatin [61825-94-3]

Research Use Only
AG-CR1-3592
AdipoGen Life Sciences
CAS Number61825-94-3
Product group Chemicals
Estimated Purity>98%
Molecular Weight397.3
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Oxaliplatin [61825-94-3]
  • Delivery Days Customer
    10
  • CAS Number
    61825-94-3
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Non-hazardous,Warning
  • Molecular Formula
    C8H14N2O4Pt
  • Molecular Weight
    397.3
  • Scientific Description
    Chemical. CAS: 61825-94-3. Formula: C8H14N2O4Pt. MW: 397.3. Potent platinum-based antineoplastic agent with wide spectrum anticancer activity. Anticancer compound. Forms inter- and intrastrand DNA adducts/crosslinks, consequently blocking DNA replication and transcription and inducing cell death. Shows antitumor activity in cisplatin resistant cell lines. Shows better biochemical, pharmacological and cytotoxic properties than cisplatin (Prod. No. AG-CR1-3590) and carboplatin (Prod. No. AG-CR1-3591). Apoptosis inducer. Targets other proteins and enzymes. Anticancer activity and antitumor specificity depends on selective uptake through human organic cation transporters 1 (OCT1) and OCT2. Neurotoxic profile depends on organic cation transporter 2 (OCT2) uptake. - Potent platinum-based antineoplastic agent with wide spectrum anticancer activity [2, 7-9]. Anticancer compound. Forms inter- and intrastrand DNA adducts/crosslinks, consequently blocking DNA replication and transcription and inducing cell death [1, 4, 7, 10, 13]. Shows antitumor activity in cisplatin resistant cell lines [3, 8]. Shows better biochemical, pharmacological and cytotoxic properties than cisplatin (Prod. No. AG-CR1-3590) and carboplatin (Prod. No. AG-CR1-3591) [5, 7, 8]. Apoptosis inducer [10, 11]. Targets other proteins and enzymes [6]. Anticancer activity and antitumor specificity depends on selective uptake through human organic cation transporters 1 (OCT1) and OCT2 [12]. Neurotoxic profile depends on organic cation transporter 2 (OCT2) uptake [14].
  • SMILES
    O=C1O[Pt]2(N[C@H]3CCCC[C@@H]3N2)OC1=O
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers: L. Pendyala, et al.; Cancer Lett. 97, 177 (1995)
  • Oxaliplatin: mechanism of action and antineoplastic activity: E. Raymond, et al.; Semin. Oncol. 25, 4 (1998) (Review)
  • Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells: A Nehme, et al.; Br. J. Cancer 79, 1104 (1999)
  • Oxaliplatin-induced damage of cellular DNA: J.M. Woynarowski, et al.; Mol. Pharmacol. 58, 920 (2000)
  • What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin? J. Lokich; Cancer Invest. 19, 756 (2001)
  • Biomolecular targets for platinum antitumor drugs: R.N. Bose; Mini Rev. Med. Chem. 2, 103 (2002)
  • Cellular and molecular aspects of drugs of the future: oxaliplatin: A.M. Di Francesco, et al.; Cell. Mol. Life Sci. 59, 1914 (2002) (Review)
  • Cellular and molecular pharmacology of oxaliplatin: E. Raymond, et al.; Mol. Cancer Ther. 1, 227 (2002)
  • New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA: J. Reedijk; PNAS 100, 3611 (2003)
  • DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells: S. Faivre, et al.; Biochem. Pharmacol. 66, 225 (2003)